Welcome and good morning on our behalf as well. We are glad to present another strong quarter. So let's start with the overall highlights. Demand improved during the quarter for the majority of our companies, with strongest order intake growth for companies with customers in the medtech and pharma area, within energy, and also the engineering industry. Organic growth was plus 6% with all five business areas improving and a book-to-bill ratio above one. Net sales growth was 13%. Due to acquisitions and strong organic sales of 5%. EBITA margin strengthened from 14.6% to 15.3%, and our cash flow increased by 20%. We have been successful on the acquisition side, with 13 acquisitions announced so far this year, and the activity remains at a high level.
Looking more specifically at the top-line development, order intake improved in all business areas and the majority of our companies; despite Q3 normally being a weak book-to-bill quarter, it was slightly positive in this quarter at 101%. And this, also despite the high sales level, order backlog is now 11% higher than in the same period last year. However, as noted previously, the order book increasingly consists of longer lead-time orders, reflecting continued strong energy sector demand driven by AI and data center investments. In terms of sales, acquisitions contributed with plus 8%, a sequential improvement from the 6% we had in Q2, and currency movements had no impact in the quarter. The organic development was strong, plus 5%, benefiting from the increased order backlog development of the last quarter. Three out of five business areas strengthened.
The EBITA margin strengthened in the quarter with good operational leverage as the main driver in Industrial & Engineering and Infrastructure & Construction. Life science was on a strong level last year, but improved due to margin-accretive acquisitions. Process. Energy and Water had margin improvements in many companies, but due to an increasingly higher share of project deliveries with slightly lower gross margins, the overall EBITA margin for the business area was basically unchanged. Technology and System Solutions has a strong underlying profitability, but continues to be impacted by weak performance in a few project-oriented companies in the UK, as we have talked about before.
Sorry, we missed the top-line comments here, so I will take them now instead. Or rather, the organic sales development. Moving to sales per market, the sales development in the Nordics was strong with a broad positive development in many companies and segments, with companies within energy, infrastructure, and process industry contributing positively, fueled by data center buildup in the Nordics. In the rest of Europe, Benelux and the UK. Ireland was flat from last year, but Germany, Switzerland, and Austria were up, mainly due to a broad general engineering improvement, as well as good development for single-use products for pharmaceutical production and companies with customers within energy. North America and Asia also improved, with valve sales for power generation being strong in the US on the back of the booming data center market. Total EBITA increased 19%, corresponding to an EBITA margin of 15.3% compared to 14.6% last year. EBITA margin was positively affected by the organic sales development. Development continued with strong gross margins and margin-accretive acquisitions. There have been continued price increases in many areas during the quarter, especially connected to freight and raw materials, etc. But our companies have done a really good job in passing price increases to the customers and protecting their gross margins. Looking at the sales development per business area, all business areas had organic growth in the quarter. Process, Energy and Water had the strongest growth of plus 6%, benefiting from the large order book buildup. The last quarter saw growth. Within mainly the energy segment, Life Science and Industrial & Engineering had a positive improvement in many companies, countries and segments. The single-use business was the main driver for Life Science, but many MedTech companies also improved; it is encouraging to see a broad improvement in Infrastructure & Construction and Technology & Systems Solutions. Although from somewhat easier comparables. Then we move into acquisitions. So far this year, we have welcomed 13 companies to Indutrade, with a total annual turnover of 2.1 billion SEK. Continuing the successful trend we have had now for over a year. During the quarter, we announced the two add-ons, Dorte Egelund ApS and Albiox Oy, and the electrification specialist Controlin B.V. In the Netherlands. In Q4, we have announced the acquisitions of the two life science companies, Euromed Medical Solution Sp. z.o.o. and Sinmed Sp. z o.o. zo.o. In Poland. We see Poland as an attractive market. It is a large domestic market and one of the fastest-growing economies in the EU, backed by strong funding and supporting industrial modernisation with many family-owned companies that would fit well within our group. We take strategic steps into new markets, and we have done so many times before. In northern Italy, for example, we have established a platform for continued growth in the region. We are now taking a similar approach as we step up our efforts in Poland. We also announced the acquisition of the German company Schraner GmbH in Q4. It is the first acquisition for the infrastructure and construction business area in two years, as focus has been on organic improvements in that area. We are, however, always open for acquisitions when the right opportunity arises, and Schraner is a good example of this. It is a non-cyclical company operating in a highly regulated niche with a strong position in the German fire protection systems market. We have a continued strong pipeline, paving the way for a continued good acquisition pace going forward. The acquired EBITA was on a record-high level in Q3, as can be seen on the graph to the right at 112 million SEK. Also, looking at the EBITDA margin of the acquired companies, it was at a margin-accretive level of 18.3% for the quarter and close to 18% on a rolling 12-month basis. It is good to note that this includes transaction costs, so the underlying margin is even higher. By that, I turn over to Jan Öhman to comment more on our financials.